Eyal Fima
- Co-authors
- Ahuva Bar-IlanOren HershkovitzTatyana DvorkinFuad FaresElena VoronovDaniel BenharrochAngel PorgadorRon N. Apte
- Topics
- Immunotherapy and Immune Responses (7 papers)Immune Cell Function and Interaction (6 papers)Growth Hormone and Insulin-like Growth Factors (6 papers)
- Partner nations
- IsraelUnited StatesGermany
In The Last Decade
Eyal Fima
23 papers receiving 635 citations
Peers
Comparison fields: 5 of 68
- Immunology 336
- Molecular Biology 248
- Oncology 139
- Endocrinology, Diabetes and Metabolism 94
- Genetics 72
Countries citing papers authored by Eyal Fima
This map shows the geographic impact of Eyal Fima's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Eyal Fima with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Eyal Fima more than expected).
Fields of papers citing papers by Eyal Fima
This network shows the impact of papers produced by Eyal Fima. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Eyal Fima. The network helps show where Eyal Fima may publish in the future.
Co-authorship network of co-authors of Eyal Fima
This figure shows the co-authorship network connecting the top 25 collaborators of Eyal Fima. A scholar is included among the top collaborators of Eyal Fima based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Eyal Fima. Eyal Fima is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 38 | |
| 2 | 35 | |
| 3 | Top Line Results of Once-Weekly, CTP-Modified Human GH (MOD-4023): Phase 2 Dose Finding Study in Children with GH Deficiency | 4 |
| 4 | 3 | |
| 5 | 4 | |
| 6 | Once-weekly, CTP-modified hGH (MOD-4023) is effective in growth hormone deficient adults: a phase II, dose and frequency finding study | 5 |
| 7 | 3 | |
| 8 | 1 | |
| 9 | 28 | |
| 10 | 41 | |
| 11 | 27 | |
| 12 | 39 | |
| 13 | 119 | |
| 14 | 136 | |
| 15 | 19 | |
| 16 | 47 | |
| 17 | Opposing effects of IL-1 alpha and IL-1 beta on malignancy patterns. Tumor cell-associated IL-1 alpha potentiates anti-tumor immune responses and tumor regression, whereas IL-1 beta potentiates invasiveness. | 28 |
| 18 | Expression of PKCeta in NIH-3T3 cells promotes production of the pro-inflammatory cytokine interleukin-6. | 13 |
| 19 | 34 | |
| 20 | IL-1 and pro-inflammatory cytokines produced by primary and transformed fibroblasts abrogate the tumorigenic potential of fibrosarcomas. | 5 |
About Eyal Fima
Eyal Fima is a scholar working on Immunology, Biotechnology and Endocrinology, Diabetes and Metabolism, having authored 23 papers that have together received 645 indexed citations. Recurring topics across this work include Immunotherapy and Immune Responses (7 papers), Immune Cell Function and Interaction (6 papers) and Growth Hormone and Insulin-like Growth Factors (6 papers). The work is most often cited by research in Immunology (336 citations), Endocrinology, Diabetes and Metabolism (94 citations) and Oncology (139 citations). Eyal Fima has collaborated with scholars based in Israel, United States and Germany. Frequent co-authors include Ahuva Bar-Ilan, Oren Hershkovitz, Tatyana Dvorkin, Fuad Fares, Elena Voronov, Daniel Benharroch, Angel Porgador, Ron N. Apte, Shraga Segal and Olle Björkdahl. Their work appears in journals such as Blood, The Journal of Immunology and PLoS ONE.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.